NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other board meeting date announcements
All →NPR Finance Board Meeting Date
NPR Finance will hold a board meeting on November 13, 2026 to consider unaudited financial results for the period ended September 30, 2026. The filing is an advance notice of a future meeting with no decision yet taken.
Nagreeka Capital & Infrastructure Board Meeting Date
Nagreeka Capital & Infrastructure will hold a board meeting on November 6, 2026 to consider unaudited standalone half-yearly results for the period ended September 2026. The trading window stays closed until November 9, 2026.
Yudiz Solutions Board Meeting Date
Yudiz Solutions will hold a board meeting on November 6, 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. The trading window stays closed until November 8, 2026.
NGL Fine - Chem Board Meeting Date
NGL Fine-Chem will hold a board meeting on November 6, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after results.
Mayur Leather Products Board Meeting Date
Mayur Leather Products scheduled a 4 November 2026 board meeting to approve half-year results. The trading window remains closed until results are declared.
Olympia Industries Board Meeting Date
Olympia Industries will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the results.